Formulations for Anti-Inflammatory Efficacy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".
Deadline for manuscript submissions: 31 March 2026 | Viewed by 330
Special Issue Editor
Interests: pharmaceutical and cosmetic formulations; pharmacy; pharmacotechnics; cosmetology; cosmetics
Special Issue Information
Dear Colleagues,
Anti-inflammatories are a class of drugs widely used in medical practice due to the fact that the inflammatory process is a central pathophysiological mechanism in numerous diseases, both acute and chronic. Proper control of this process is essential to preserve tissue function and the patient's quality of life.
Effectiveness in the control of inflammatory mechanisms requires more than just active ingredients; efficient pharmaceutical formulations are essential, as they directly influence therapeutic efficacy, the safety of the prepared medication, and patient adherence.
Therefore, this special edition focuses on this issue, aiming to understand updates on innovative formulations and technologies capable of increasing efficacy, safety, and patient adherence to the use of such medications.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- Novel synthetic antiinflamatory actives;
- Novel anti-inflammatory bioactives;
- Development of oral anti-inflammatory formulations;
- Development of topical anti-inflammatory formulations;
- Development of parenteral anti-inflammatory formulations;
- New methodologies to evaluate anti-inflammatory formulations.
Dr. Bruna Chiari-Andréo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- inflammation
- steroidal anti-inflammatory drugs
- non-steroidal anti-inflammatory drugs
- natural anti-inflammatory drugs
- efficacy and safety.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
